Aspirin for VTE Prophylaxis After Joint Replacement
Getting the agent, dose, and duration wrong exposes the patient to either a preventable pulmonary embolism or an avoidable bleeding or wound complication.
Takeaways
- Without any prophylaxis, VTE is the expected outcome, not the exception. In a placebo-controlled trial, venographic VTE occurred in 41.9% of THA patients and 60.8% of TKA patients receiving no chemoprophylaxis, the baseline risk every current regimen is built to lower (Fuji et al, J Orthop Sci 2008;13:442-451, PMID 18843459).
- The AAOS does not mandate a specific prophylactic agent after elective THA or TKA. The 2011 guideline directs standard-risk patients to receive pharmacologic prophylaxis plus mechanical compression and early mobilization, naming only prior VTE as a factor warranting further risk assessment, while leaving agent choice to clinical judgment (Mont et al, J Am Acad Orthop Surg 2011;19:768-776, PMID 22134209).
- ACCP lists 8 agents, including aspirin, as equally acceptable first-line options. LMWH, fondaparinux, dabigatran, apixaban, rivaroxaban (THA/TKA only), low-dose unfractionated heparin, warfarin, and aspirin all carry the same Grade 1B recommendation for a minimum of 10 to 14 days (Falck-Ytter et al, Chest 2012;141:e278S-e325S, PMID 22315265).
- Extending prophylaxis to 35 days is a weak suggestion, not a strong recommendation. ACCP grades extended thromboprophylaxis up to 35 days as Grade 2B, markedly weaker evidence than the Grade 1B backing the choice of agent itself (Falck-Ytter et al, Chest 2012;141:e278S-e325S, PMID 22315265).
- ASH treats aspirin and anticoagulants as interchangeable for standard-risk patients. The 2019 ASH guideline gives only a conditional recommendation for using either aspirin or an anticoagulant after THA/TKA, plus a separate conditional preference for a DOAC over LMWH when anticoagulation is chosen (Anderson et al, Blood Adv 2019;3:3898-3944, PMID 31794602).
- Extended aspirin was not significantly different from rivaroxaban for preventing symptomatic VTE. In EPCAT2, 3,424 patients received 5 days of rivaroxaban then were randomized to continue rivaroxaban or switch to aspirin 81 mg daily. Symptomatic VTE occurred in 0.64% of the aspirin group versus 0.70% of the rivaroxaban group, with similar major bleeding (Anderson et al, N Engl J Med 2018;378:699-707, PMID 29466159).
- The aspirin dose that lowers infection risk is 81 mg, not 325 mg. Among 15,825 arthroplasty patients on aspirin prophylaxis, twice-daily 325 mg dosing was linked to a higher periprosthetic joint infection rate than 81 mg dosing (0.35% versus 0.10%, odds ratio 2.59) (Najafi et al, J Arthroplasty 2022;37:2444-2448, PMID 35843380).
- By 2026, low-dose aspirin has moved from an accepted option to the preferred agent. The 2022 International Consensus Meeting endorsed low-dose aspirin for VTE prophylaxis across risk profiles, and a 141,334-patient THA registry confirmed lower rates of VTE, bleeding, infection, and death with aspirin monotherapy than with alternative anticoagulants, in both high and low-risk patients (Tummala et al, J Arthroplasty 2026, PMID 41825492).